Navigation Links
Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Date:11/16/2009

WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by the uptake of three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/AstraZeneca/Takeda. The increasing prevalence of MRSA and the uptake of several premium-priced emerging therapies will drive the MRSA market to increase from $740 million in 2008 to more than $1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Methicillin-Resistant Staphylococcus Aureus finds that Theravance/Astellas's telavancin, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline will capture more than one-third of the overall MRSA market in 2018. The two novel first-in-class anti-MRSA cephalosporins -- ceftobiprole and ceftaroline -- which are both expected to launch by 2011, will have a significant impact on the market by bringing cephalosporins to the forefront of the array of drug classes used to treat MRSA. Owing to their broad-spectrum and expanded activity against MRSA, ceftobiprole and ceftaroline are well-poised for use as first-line therapies for suspected MRSA infections in the hospital setting.

"Ceftobiprole and ceftaroline offer safe, effective, and convenient monotherapy options for simplified empiric treatment of MRSA infections in place of existing combination therapy," said Decision Resources Analyst Hemali Patel, Ph.D. "Although we anticipate robust competition between these two agents due to their similar profiles, we forecast that ceftobiprole and ceftaroline will each achieve significant commercial success and together will represent 20 percent of the overall MRSA market in 2018."

The report also finds that, in contrast to current therapies consisting largely of narrow-spectrum anti-MRSA agents, late-stage anti-MRSA emerging therapies are comprised of numerous broad-spectrum agents spanning several antibiotic drug classes. In addition, the pipeline for MRSA is also characterized by new therapies being developed in both intravenous and oral formulations (e.g., Trius Therapeutics' torezolid, Rib-X's delafloxacin, Paratek/Novartis's PTK-0796) which could address the growing need for oral MRSA therapies for both the hospital and community settings.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                  Decision Resources, Inc.
    Christopher Comfort                 Elizabeth Marshall
    781-296-2597                        781-296-2563
    ccomfort@dresources.com             emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
2. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
3. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
4. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
5. Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
8. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
9. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance ... insurance and financial preparation services, is providing an update on a charitable event ... Rock City Rescue is a locally recognized nonprofit that provides shelter and care ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
Breaking Medicine News(10 mins):